Study design of a randomised, placebo-controlled trial of nintedanib in children and adolescents with fibrosing interstitial lung disease

Childhood interstitial lung disease (chILD) comprises >200 rare respiratory disorders, with no currently approved therapies and variable prognosis. Nintedanib reduces the rate of forced vital capacity (FVC) decline in adults with progressive fibrosing interstitial lung diseases (ILDs). We present...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:ERJ Open Res
Main Authors: Deterding, Robin, Griese, Matthias, Deutsch, Gail, Warburton, David, DeBoer, Emily M., Cunningham, Steven, Clement, Annick, Schwerk, Nicolaus, Flaherty, Kevin R., Brown, Kevin K., Voss, Florian, Schmid, Ulrike, Schlenker-Herceg, Rozsa, Verri, Daniela, Dumistracel, Mihaela, Schiwek, Marilisa, Stowasser, Susanne, Tetzlaff, Kay, Clerisme-Beaty, Emmanuelle, Young, Lisa R.
Formato: Artigo
Idioma:Inglês
Publicado em: European Respiratory Society 2021
Assuntos:
Study Protocols
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8215331/
https://ncbi.nlm.nih.gov/pubmed/34164554
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1183/23120541.00805-2020
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados